Concord Biotech Ltd

BSE Code : 543960
NSE Symbol : CONCORDBIO
ISIN : INE338H01029
Industry :PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN

Trade Now

Get Quotes

1,620.60 -74.50(-4.40%)

Open Price (₹)

1,695.00

Prev. Close (₹)

1,695.10

Volume (No’s)

127,084

Market Cap (₹)

16,954.10

Low Price (₹)

1,617.00

High Price (₹)

1,695.00

Chart

Technical Chart

Corparate Information

Financials

Corporate Action

Board Meetings

Start Date	End Date	Purpose
04-Aug-2025	08-Aug-2025	Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2025 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results for the First quarter ended on June 30 2025 along with limited review report Outcome of Board Meeting held today , Friday, August 08, 2025- Unaudited Financial Results for the First quarter ended on June 30, 2025 (As per BSE Announcement Dated on 08.08.2025)
23-May-2025	29-May-2025	Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 inter alia to consider and approve the audited Standalone and Consolidated Financial results of the company for the quarter and year ended March 31 2025 Board Meeting Outcome for Outcome Of Board Meeting Held On 29Th May2025 The Board has recommended Dividend of Rs. 10.70 per Equity Share of face value of Re. 1 each fully paid up for the Financial Year 2024-25, subject to approval by shareholders of the Company at the ensuing AGM. Outcome of Board Meeting held today i.e. Thursday, May 29, 2025- To Audited Financial Results for the quarter and Financial Year ended on March 31, 2025 and to approve other agendas. (As Per BSE Announcement Dated on 29.05.2025)
04-Mar-2025	04-Mar-2025	To Invest in M/s Clean Max Everglades Private limited Rs. 6,09,58,836/- through Right Issue for installation of Hybrid renewable energy Plant
24-Jan-2025	13-Feb-2025	Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and nine months period ended 31 December 2024. Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we enclose herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the Third quarter and Nine months ended on December 31, 2024, along with the Limited Review Report with Unmodified Opinion issued by M/s. BSR & Co. LLP, the Statutory auditors. (As Per BSE Announcement Dated on: 13/02/2025)
06-Nov-2024	11-Nov-2024	Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2024 inter alia to consider and approve The Standalone and Consolidated Unaudited Financial Results for the Second quarter and half year ended September 30 2024 along with limited review report to be issued by the Statutory Auditors and to consider other business matters if any Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we enclose herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the Second quarter and half year ended September 30, 2024, along with the Limited Review Report with Unmodified Opinion issued by M/s. BSR & Co. LLP, the Statutory auditors. Read less.. (As Per BSE Announcement Dated on 11.11.2024)